

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

INSIDE INFORMATION ANNOUNCEMENT

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**” together with its subsidiaries, the “**Group**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”).

The board of directors (the “**Directors**”) of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, Techdow Pharma Italy S.R.L., a wholly owned subsidiary of the Company (“**Techdow Italy**”), is suspected to have been defrauded by a criminal syndicate as a result of telecom fraud, involving an amount of approximately 11.7 million euros (the “**Incident**”). The Company promptly reported the Incident to the police after discovering the fraud. The police have opened a case file and commenced criminal investigations into the matter. At the same time, the Company is fully cooperating with the police investigation and making every effort to minimize the loss.

The management of the Company has promptly alerted the Board, independent non-executive Directors and the audit committee of the Board of the Incident, and its preliminary assessment indicates that the Incident is an isolated event. The management of the Company confirmed that the Company’s production and operation remain normal. The Company’s management is reviewing the Incident carefully and has proactively adopted measures to enhance its internal control management, corporate governance and risk awareness.

The issue is of serious concern to the Company's management, who has sent personnel to Techdow Italy to handle the Incident. As the investigation into the Incident is ongoing, the outcome is still uncertain, and may have potential impacts on the Company's financial statements for the year ended 31 December 2023 ("FY2023").

The Company is monitoring the investigation of the Incident with great concern and will cooperate fully with the police to resolve the case and recover any losses without delay.

The Board considers that the overall operation of the Group as a whole remains normal and its financial position remains solid.

The Company will make further announcement(s) to keep the Shareholders and potential investors informed of any significant developments in respect of the Incident as and when appropriate. Shareholders and potential investors of the Company are advised to read carefully the annual results announcement of the Company for FY2023 ("**Annual Results**"), which is expected to be published in March 2024 pursuant to the requirements of the Listing Rules, and any potential profit warning announcement in relation to the Annual Results.

Shareholders and potential investors of the Company are reminded that the information provided in this announcement is based on the currently available information to the Board. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
January 15, 2024

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.